HK1211620A1 - Natural killer cells and uses thereof - Google Patents

Natural killer cells and uses thereof Download PDF

Info

Publication number
HK1211620A1
HK1211620A1 HK15112433.3A HK15112433A HK1211620A1 HK 1211620 A1 HK1211620 A1 HK 1211620A1 HK 15112433 A HK15112433 A HK 15112433A HK 1211620 A1 HK1211620 A1 HK 1211620A1
Authority
HK
Hong Kong
Prior art keywords
methods
cells
cell populations
populations
natural killer
Prior art date
Application number
HK15112433.3A
Other languages
English (en)
Chinese (zh)
Inventor
埃裡克‧勞
埃里克‧劳
康琳
弗拉基米爾‧揚科維奇
弗拉基米尔‧扬科维奇
張小葵
张小葵
斯圖爾特‧阿博特
斯图尔特‧阿博特
羅伯特‧
罗伯特‧J‧哈黎里
‧哈黎裡
Original Assignee
人类起源公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 人类起源公司 filed Critical 人类起源公司
Publication of HK1211620A1 publication Critical patent/HK1211620A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/44—Thiols, e.g. mercaptoethanol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/46—Amines, e.g. putrescine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2317—Interleukin-17 (IL-17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK15112433.3A 2012-08-13 2013-08-13 Natural killer cells and uses thereof HK1211620A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261682706P 2012-08-13 2012-08-13
US61/682,706 2012-08-13
US201361799211P 2013-03-15 2013-03-15
US61/799,211 2013-03-15
PCT/US2013/054677 WO2014028453A2 (en) 2012-08-13 2013-08-13 Natural killer cells and uses thereof

Publications (1)

Publication Number Publication Date
HK1211620A1 true HK1211620A1 (en) 2016-05-27

Family

ID=50101590

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15112433.3A HK1211620A1 (en) 2012-08-13 2013-08-13 Natural killer cells and uses thereof

Country Status (12)

Country Link
US (1) US20150225697A1 (https=)
EP (2) EP3722416A1 (https=)
JP (4) JP2015526088A (https=)
KR (3) KR20150063374A (https=)
CN (2) CN114134113A (https=)
AU (3) AU2013302853A1 (https=)
BR (1) BR112015003149A2 (https=)
CA (1) CA2881792C (https=)
HK (1) HK1211620A1 (https=)
MX (1) MX2015001871A (https=)
RU (2) RU2015108761A (https=)
WO (1) WO2014028453A2 (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
AU2014240083C1 (en) 2013-03-15 2019-10-24 Celgene Corporation Modified T lymphocytes
KR20160098244A (ko) * 2013-11-15 2016-08-18 안트로제네시스 코포레이션 사람 태반 관류액 세포를 포함하는 조성물, 상기 세포의 부분모집단 및 이의 용도
US20180021378A1 (en) * 2014-12-31 2018-01-25 Anthrogenesis Corporation Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cells
NZ733213A (en) * 2014-12-31 2022-10-28 Celularity Inc Natural killer cells and uses thereof
WO2016162827A1 (en) * 2015-04-09 2016-10-13 Universita' Degli Studi Di Genova Population of human lymphoid precursors, method for their identification and uses thereof
JP6073417B2 (ja) * 2015-06-26 2017-02-01 チャ バイオテック カンパニー リミテッド 自然殺害細胞増殖方法、及び自然殺害細胞増殖用の組成物
CA2998292A1 (en) * 2015-09-11 2017-03-16 Emercell Sas Pooled nk cells from umbilical cord blood associated with antibodies and their uses for the treatment of disease
ES2980794T3 (es) 2015-09-15 2024-10-03 Acerta Pharma Bv Combinaciones terapéuticas de un inhibidor de CD19 y un inhibidor de BTK
MY201637A (en) * 2015-10-15 2024-03-06 Celularity Inc Natural killer cells and ilc3 cells and uses thereof
CA3003923A1 (en) * 2015-11-05 2017-05-11 Glycostem Therapeutics B.V. Composition for use in immunotherapy
CN106701677A (zh) * 2015-11-18 2017-05-24 深圳爱生再生医学科技有限公司 Nk细胞的体外扩增培养方法
AU2017215955B2 (en) * 2016-02-01 2020-01-23 GC Cell Corporation Medium composition for cryopreservation of cell and use thereof
CN109843304A (zh) * 2016-05-07 2019-06-04 细胞结构公司 使用自然杀伤细胞治疗急性髓性白血病和多发性骨髓瘤的方法
KR101926166B1 (ko) * 2016-05-24 2018-12-06 재단법인 아산사회복지재단 수용체 시너지 활성을 이용한 nk 세포의 활성도 검사 방법 및 이를 이용한 nk 세포의 활성도가 관련된 질환의 진단 방법
KR101866827B1 (ko) * 2016-09-28 2018-07-19 한국원자력의학원 방사선 조사된 말초혈액단핵구를 이용한 고효율 자연살상세포의 제조방법 및 이를 이용한 항암 면역 세포치료제 조성물
WO2018088875A2 (ko) 2016-11-14 2018-05-17 주식회사 파이안에스테틱스 외래 미토콘드리아를 포함하는 자연살해세포 및 이를 포함하는 약학적 조성물
AU2017377309B9 (en) * 2016-12-14 2021-06-03 Otsuka Pharmaceutical Factory, Inc. Mammalian cell cryopreservation liquid
JP2020503043A (ja) * 2016-12-30 2020-01-30 セルラリティ インコーポレイテッド 遺伝子改変されたナチュラルキラー細胞
WO2018160673A1 (en) * 2017-02-28 2018-09-07 University Of Central Florida Research Foundation, Inc. Pm21 particles to improve bone marrow homing of nk cells
US12129487B2 (en) * 2017-03-27 2024-10-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to obtain lymphoid progenitors
CN113061577A (zh) * 2017-09-05 2021-07-02 四川新生命干细胞科技股份有限公司 一种高纯度nk细胞的分离培养方法
CA3077325A1 (en) * 2017-09-28 2019-04-04 Celularity Inc. Tumor suppression using human placenta-derived intermediate natural killer (pink) cells in combination with an antibody
IL273757B2 (en) 2017-10-02 2025-01-01 Gamida Cell Ltd Growing and using NK cell populations
CN107904175B (zh) * 2017-12-29 2018-09-25 广州沙艾生物科技有限公司 用于免疫细胞的诱导扩增的培养箱
JP2021525066A (ja) * 2018-05-30 2021-09-24 グリコステム セラピューティクス ベスローテン フェンノートシャップ Ｃａｒ ｎｋ細胞
AU2019300782B2 (en) 2018-07-10 2023-12-21 Immunitybio, Inc. Generating CIK NKT cells from cord blood
CN109337870B (zh) * 2018-12-24 2020-07-03 广东暨德康民生物科技有限责任公司 人Vγ9Vδ2T细胞扩增方法与培养基
KR102032384B1 (ko) * 2019-03-05 2019-11-08 주식회사 온코인사이트 제대혈 단핵세포에서의 자연살해세포의 제조 방법
KR102216710B1 (ko) * 2019-03-27 2021-02-17 신지섭 Nk세포배양배지용 첨가조성물, 상기 첨가조성물을 이용한 nk세포배양방법 및 상기 배양방법으로 얻어진 피부트러블개선용 화장료조성물
KR20200122261A (ko) * 2019-04-17 2020-10-27 (주)차바이오텍 항암 활성이 증가된 자연살해세포 및 그의 면역 치료 용도
KR102233660B1 (ko) * 2019-05-15 2021-03-30 (주)포에버엔케이 효율적 자연살해세포 배양방법 및 이의 배지첨가 키트
IT201900023922A1 (it) * 2019-12-13 2021-06-13 Univ Degli Studi Genova Popolazione cellulare progenitrice CD56-CD16+PerfnegCD7- e progenie cellulare NK CD94/NKG2C+KIR+CD57+ originata da detta popolazione cellulare CD56-CD16+PerfnegCD7-, loro ottenimento e loro usi
EP4114415A1 (en) 2020-03-06 2023-01-11 Sorrento Therapeutics, Inc. Innate immunity killer cells targeting psma positive tumor cells
CN112029721A (zh) * 2020-09-09 2020-12-04 广东昭泰体内生物医药科技有限公司 一种活性增强型nk细胞的制备方法
CN112029722A (zh) * 2020-09-09 2020-12-04 广东昭泰体内生物医药科技有限公司 一种nk细胞培养基及其应用
CN112266900A (zh) * 2020-10-30 2021-01-26 广东康盾生物工程技术有限公司 一种car-nk细胞的培养方法
CN112708675A (zh) * 2020-12-25 2021-04-27 中山大学肿瘤防治中心 骨髓nk细胞联合mcl1抑制剂在抗白血病中的应用
CN113416701B (zh) * 2021-07-28 2023-05-09 新疆西部赛澳生物科技有限责任公司 一种nk细胞培养基及培养方法
EP4389877A4 (en) * 2021-08-06 2025-09-03 Inst Zoology Cas RIC CELL AND ITS PREPARATION METHOD AND USE
KR20240063899A (ko) * 2021-09-08 2024-05-10 가부시키가이샤 가이아바이오메디신 세포의 처리 방법
CN113801846B (zh) * 2021-09-22 2024-06-04 南京艾尔普再生医学科技有限公司 一种从人诱导多能干细胞分化为自然杀伤细胞的方法
CN114891856B (zh) * 2022-05-16 2025-08-15 武汉科技大学 大队列样本单细胞富集和混样建库测序方法
CN114736859B (zh) * 2022-06-13 2022-08-19 广东先康达生物科技有限公司 一种脐带血nk细胞的培养液及培养方法
WO2024101863A1 (ko) * 2022-11-07 2024-05-16 마루테라퓨틱스 주식회사 줄기세포 기원 및 발현 마커에 따른 nk 세포 분화 효율 증진 방법
US20240279607A1 (en) * 2023-02-17 2024-08-22 FullHope Biomedical Co., Ltd. Pharmaceutical composition comprising modified natural killer cells and antigen-specific t cells, manufacturing method thereof, and method of using the same
CN117603809A (zh) * 2023-12-06 2024-02-27 威海紫光科技园有限公司 一种应用于nk细胞制备过程中复苏的温度控制方法及系统
CN117946971B (zh) * 2023-12-14 2025-07-15 深圳泽医细胞治疗集团有限公司 一种用于诱导C1型iNKT细胞的培养基、培养方法及其应用
WO2025160465A1 (en) 2024-01-26 2025-07-31 Celularity Inc. A method of treating signs or symptoms of the aging process
CN118370308B (zh) * 2024-04-18 2025-11-11 维赛(佛山)生物科技有限公司 一种临床用犬自然杀伤细胞冷藏保存液及其制备方法和应用
WO2025225667A1 (ja) * 2024-04-26 2025-10-30 日機装株式会社 凍結された腎細胞凝集体を含むプレート、それを用いた薬物動態検査用キット、毒性検査用キット及び創薬開発用キット
CN120005821B (zh) * 2025-04-21 2025-07-25 上海华颜医药科技有限公司 一种免疫细胞的培养方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
US5190556A (en) 1991-03-19 1993-03-02 O.B. Tech, Inc. Cord cutter sampler
US5552267A (en) 1992-04-03 1996-09-03 The Trustees Of Columbia University In The City Of New York Solution for prolonged organ preservation
US5372581A (en) 1993-07-21 1994-12-13 Minneapolis Children's Services Corporation Method and apparatus for placental blood collection
EP2305795B1 (en) 2000-12-06 2019-07-03 Celularity, Inc. Method of collecting placental stem cells
EP2316918B1 (en) 2001-02-14 2015-07-01 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
US20030124091A1 (en) * 2001-10-26 2003-07-03 Large Scale Biology Corporation Endothelial cell derived hematopoietic growth factor
US20030187515A1 (en) 2002-03-26 2003-10-02 Hariri Robert J. Collagen biofabric and methods of preparing and using the collagen biofabric
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US7147626B2 (en) 2004-09-23 2006-12-12 Celgene Corporation Cord blood and placenta collection kit
ZA200804717B (en) 2005-12-29 2010-02-24 Anthrogenesis Corp Improved composition for collecting and preserving a placental stem cells and methods of using the composition
PL2471907T3 (pl) 2005-12-29 2019-07-31 Celularity, Inc. Populacje komórek macierzystych łożyska
ES2638435T3 (es) * 2007-03-27 2017-10-20 Ipd-Therapeutics B.V. Métodos y medios para proliferación de células madre y posterior generación y expansión de células progenitoras, así como también producción de células efectoras como terapéuticos clínicos
MX342995B (es) * 2010-07-13 2016-10-21 Anthrogenesis Corp Métodos de generar células asesinas naturales.
US9476029B2 (en) * 2010-11-13 2016-10-25 Lung-Ji Chang Ex vivo development, expansion and in vivo analysis of a novel lineage of dendritic cells
ES2856825T3 (es) * 2011-03-18 2021-09-28 Glycostem Therapeutics B V Generación de células NK y progenitores de células NK

Also Published As

Publication number Publication date
WO2014028453A3 (en) 2014-10-09
AU2022200976A1 (en) 2022-03-03
WO2014028453A2 (en) 2014-02-20
JP2018183161A (ja) 2018-11-22
CN114134113A (zh) 2022-03-04
CA2881792C (en) 2024-02-27
RU2015108761A (ru) 2016-10-10
JP2020188782A (ja) 2020-11-26
MX2015001871A (es) 2015-09-21
AU2013302853A1 (en) 2015-03-05
KR20150063374A (ko) 2015-06-09
EP2882847A2 (en) 2015-06-17
KR20220166873A (ko) 2022-12-19
JP2015526088A (ja) 2015-09-10
AU2019204020A1 (en) 2019-06-27
BR112015003149A2 (pt) 2017-08-08
KR20210076150A (ko) 2021-06-23
CN105008516A (zh) 2015-10-28
JP2023036639A (ja) 2023-03-14
EP3722416A1 (en) 2020-10-14
EP2882847A4 (en) 2016-03-23
US20150225697A1 (en) 2015-08-13
RU2019124982A (ru) 2019-09-02
CA2881792A1 (en) 2014-02-20

Similar Documents

Publication Publication Date Title
HK1211620A1 (en) Natural killer cells and uses thereof
MY201637A (en) Natural killer cells and ilc3 cells and uses thereof
BR112013000822A2 (pt) método e método de duas etapas para a produção de uma população de células exterminadoras naturais (nk) ativadas, população de células nk ativadas e método para suprimir a proliferação de células tumorais
BR112017014269A2 (pt) células exterminadoras naturais e usos das mesmas
PH12021551241A1 (en) Expansion of natural killer cells and ilc3 cells with novel aromatic compounds
MX2024002353A (es) Celulas asesinas naturales modificadas geneticamente.
PH12014502767A1 (en) Interleukin-2 fusion proteins and uses thereof
SG178991A1 (en) Anti-gitr antibodies
AU2012298537A8 (en) Bispecific T cell activating antigen binding molecules
SG10201809452RA (en) Cell culture compositions with antioxidants and methods for polypeptide production
WO2012140127A3 (en) Method for priming of t cells
MX375786B (es) Biosintesis microbiana de ergotioneina.
PH12013502462B1 (en) Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure and dendritic cells
WO2012083024A8 (en) Treatment of spinal cord injury and traumatic brain injury using placental stem cells
MX2013004353A (es) Produccion recombinante de n-propanol e isopropanol.
IN2014DN06104A (https=)
MX2021009554A (es) Produccion de virus en cultivos celulares.
EP4306174A3 (en) Composition for controlled ovarian stimulation
SG10201901559SA (en) Retinal ganglion cells and progenitors thereof
IN2015MN00436A (https=)
WO2008143047A1 (ja) 樹状細胞の製造方法
AU2014225575A8 (en) Individualized high purity hepatocellular carcinoma stem cells, methods and use of the same
WO2011121051A3 (fr) Preparation issue d'une culture in vitro de cellules dedifferenciees non elicitees d'arganier, leur utilisation pour le traitement du vieillissement cutane, de l'inflammation et de la cicatrisation, et leur obtention
WO2014133728A3 (en) Hhla2 as a novel inhibitor of human immune system and uses thereof
HK1257882A1 (zh) 通过t细胞疗法来治疗多发性骨髓瘤和浆细胞性白血病的方法